Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT)

被引：36

作者：

Boyer, M. J.

Blackhall, F. H.

Park, K.

Barrios, C. H.

Krzakowski, M. J.

Taylor, I.

Liang, J. Q.

Denis, L. J.

O'Connell, J. P.

Ramalingam, S. S.

机构：

[1] Sydney Canc Ctr, Camperdown, NSW, Australia

[2] Christie NHS Fdn Trust, Manchester, Lancs, England

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[4] Hosp Sao Lucas PUCRS, Porto Alegre, RS, Brazil

[5] Maria Sklodowska Curie Mem Canc Ctr, Inst Oncol, Warsaw, Poland

[6] Pfizer Inc, New London, CT USA

[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

来源：

关键词：

D O I：

10.1200/jco.2010.28.18_suppl.lba7523

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA7523

引用

页数：1